Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia.
MLAA-34 is a newly identified monocytic leukemia-associated antigen. Previous data indicated that MLAA-34 might be a novel anti-apoptosis factor related closely to carcinogenesis or progression of acute monocytic leukemia. The over-expression of MLAA-34 is intuitively expected to be associated with unfavorable clinical features in acute myeloid leukemia. However, there have been no clinical studies about the prognostic relevance of MLAA-34 expression in human malignancies. This study was done to investigate the clinical relevance of the expression of MLAA-34 in de novo acute myeloid leukemia. In 126 patients with de novo acute myeloid leukemia, the level of MLAA-34 expression and protein expression ratio were determined by using quantitative reverse transcriptase-PCR and western blot, respectively. The results were analyzed with respect to the patients' clinical features and treatment outcomes. Both MLAA-34 expression rates and expression levels were found to be higher in patients with the French-American-British classification subtype M5, and the expression levels were also higher in patients with a leukocyte number of ≥ 20 × 10(9)/L and patients with extramedullary disease. In addition, MLAA-34 over-expression (≥ median expression) was associated with an unfavorable day 7 response to induction chemotherapy and also associated with a poor survival rate. In multivariate analysis, high MLAA-34 levels was independently associated with a poorer relapse-free survival and overall survival in AML patients. In conclusion, our data indicate that MLAA-34 may be used as a prognostic marker for treatment decision-making in acute monocytic leukemia through validation by further studies.
Department of Clinical Hematology, 2nd Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, 157, 5th West Road, 710004, Xi'an, Shaanxi, People's Republic of China.
Jianqiang
J
Zhao
Aili
A
He
Wanggang
W
Zhang
Xin
X
Meng
Liufang
L
Gu
D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000951:Antigens, Neoplasm; D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor; C534238:CAB39L protein, human
Blut. 1988 Aug;57(2):91-5
3165680
Leuk Lymphoma. 2000 Sep;39(1-2):1-18
10975379
Blood. 2001 Sep 15;98(6):1752-9
11535508
Blood. 2001 Sep 15;98(6):1746-51
11535507
Haematologica. 2000 Dec;85(12):1285-90
11114136
Cancer Res. 1994 Jan 15;54(2):370-3
8275471
Hematology Am Soc Hematol Educ Program. 2002;:73-110
12446420
Br J Haematol. 1989 Apr;71(4):493-7
2653407
Leuk Res. 2005 May;29(5):503-9
15755502
Blood. 1999 Nov 15;94(10):3315-24
10552940
Oncogene. 2004 Mar 15;23(11):2009-15
15021888
Genes Dev. 1999 Feb 1;13(3):239-52
9990849
Cancer. 2001 Jun 1;91(11):2026-32
11391581
Blood. 2001 Jun 15;97(12):3727-32
11389009
Blood. 2003 Jan 1;101(1):64-70
12393605
Semin Cancer Biol. 2004 Aug;14(4):231-43
15219616
Blood. 2001 Nov 1;98(9):2603-14
11675328
Science. 1991 Sep 27;253(5027):1550-3
1654597
Clin Cancer Res. 2000 May;6(5):1796-803
10815900
Cell. 2005 Sep 23;122(6):835-47
16179254
Lancet. 2006 Nov 25;368(9550):1894-907
17126723
Haematologica. 2007 Jun;92(6):763-70
17550848
Blood. 2005 Aug 1;106(3):938-45
15827130
Blood. 2002 Dec 15;100(13):4325-36
12393746
Cancer Immunol Immunother. 2009 Feb;58(2):281-90
18592235
Oncologist. 2010;15(4):350-9
20413640
J Clin Oncol. 1996 Sep;14(9):2486-94
8823327
Apoptosis. 2004 Nov;9(6):705-15
15505413
Cancer Res. 1998 Nov 15;58(22):5071-4
9823313
Haematologica. 2006 Dec;91(12):1653-61
17145602
Blood. 1995 Aug 15;86(4):1292-5
7632935
Blood. 2007 Jan 15;109(2):471-7
16990595
Methods. 2001 Dec;25(4):402-8
11846609
Leuk Lymphoma. 2000 Dec;40(1-2):105-12
11426610
Hepatology. 2000 May;31(5):1080-5
10796883
Cell Res. 2000 Sep;10(3):169-77
11032169